Exact Sciences Director Files Intent to Sell $120k in Stock (EXAS)
EXACT SCIENCES CORP
Subscribe to track EXAS
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Exact Sciences Director Files Intent to Sell $120k in Stock (EXAS)
Company: EXACT SCIENCES CORP (EXAS) Form: 144 | Filed: 2025-10-09 Significance: Low
Insider: Doyle James Edward Title: Director | Relationship: Director
Transaction (Proposed): • Type: Proposed Sale • Shares: 2,000 • Price: ~$60.00 • Value: $120,000 • Owned After: Not Disclosed
Key Insight: A director has filed a notice of intent to sell a small lot of shares. The sale is part of a pre-arranged trading plan, which significantly reduces its market signaling value.
Market Context: The filing notes a 10b5-1 trading plan was adopted on March 9, 2025, indicating this is a scheduled liquidation rather than a reaction to recent events. A prior sale of 1,485 shares occurred in August 2025.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: EXACT SCIENCES CORP (EXAS)
Executive Summary
- Trading Significance: Low
- Key Takeaway: A non-executive director, James Doyle, has filed a Form 144 indicating an intent to sell 2,000 shares of common stock for an aggregate value of $120,000. The sale is pursuant to a pre-established 10b5-1 trading plan, making it a routine, low-significance event.
- Market Impact: The market impact is expected to be neutral. The small size of the proposed sale relative to the company's market cap and the fact that it is part of a pre-scheduled plan suggest this is a personal liquidity event for the insider, not a reflection of their outlook on the company.
Company Information
| Field | Value |
|---|---|
| Company | EXACT SCIENCES CORP |
| Ticker Symbol | EXAS |
| CIK | 0001124140 |
| Industry | Services-Medical Laboratories |
Insider Information
| Field | Value |
|---|---|
| Name | Doyle James Edward |
| CIK | 0001614265 |
| Title/Position | Director |
| Relationship | Director |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 144 (Notice of Proposed Sale) |
| Transaction Date | 2025-10-09 (Approximate Sale Date) |
| Transaction Code | S (Sale) |
| Security Type | Common Stock |
| Shares Involved | 2,000 |
| Price Per Share | ~$60.00 (Calculated from Aggregate Value) |
| Total Value | $120,000.00 |
| Shares Owned After | Not Disclosed |
| Ownership Type | Not Disclosed |
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: Form 144 filings for sales under a 10b5-1 plan are common and generally do not cause significant price movement. The transaction value is minor for a company of Exact Sciences' size. This is not considered a bearish signal.
Volume & Sentiment
- Expected Volume Impact: Negligible. The 2,000 shares are a tiny fraction of the average daily trading volume.
- Sentiment Indicator: Neutral. The market typically discounts planned sales by non-executive insiders as they are often for personal financial planning, diversification, or tax purposes.
Investment Insights
Positive Market Indicators
- The existence of a 10b5-1 plan shows structured, long-term planning rather than a reactive decision.
Risk Factors
- While this specific transaction is low-risk, a pattern of multiple insiders selling, even under plans, could warrant closer observation.
Key Takeaways
- Planned Transaction: The sale is governed by a 10b5-1 plan adopted on March 9, 2025, removing any implication of the insider trading on non-public information.
- Low Significance: The sale is by a Director (not a C-suite executive) and the value is not substantial.
- Pattern of Sales: The filing discloses a previous sale of 1,485 shares on August 13, 2025, reinforcing the idea of a periodic, planned liquidation strategy.
Contextual Analysis
Timing Significance
The filing is a notice of intent to sell on or around October 9, 2025. As it's pre-scheduled, the timing relative to market conditions is less relevant than it would be for a discretionary trade.
Transaction Context
The most critical context is the <planAdoptionDate> of March 9, 2025. This confirms the sale is being executed under a Rule 10b5-1 trading plan, which provides an affirmative defense against insider trading allegations. This is a routine disclosure.
Company Context
Exact Sciences operates in the highly dynamic medical diagnostics space. Any analysis should consider this filing in the context of recent company news, clinical trial data, earnings reports, and competitive landscape. However, this specific filing on its own provides little new insight into the company's immediate prospects.
Risk Assessment
Risk Level: Low
Risk Factors
- This filing does not introduce any new material risk factors for the company or its stock.
Market Considerations
- The market has become adept at distinguishing between planned 10b5-1 sales and opportunistic insider selling. This transaction falls squarely in the former category.
- Investors should monitor for future filings from other key executives to see if a broader trend emerges.
IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.
Analysis generated on 2025-10-09 | Data source: SEC EDGAR
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.